Jazz Pharmaceuticals Fibromyalgia Potential Rejected by FDA
Jazz Pharmaceuticals shares slumped more than 5% in premarket trading Monday after the company announced that the FDA had denied approval for its fibromyalgia treatment, sodium oxybate. While approved to treat narcolepsy, sodi…